The DOI matches its Crossref record.
The effect of anti‐CD40 ligand antibody on B cells in human systemic lupus erythematosus
Abstract
Objective: To determine the immunologic effects of anti–CD40 ligand (anti‐CD40L) therapy in 5 patients with systemic lupus erythematosus nephritis who participated in an open‐label study of a humanized anti‐CD40L monoclonal antibody. Methods: Serum and peripheral blood mononuclear cells were obtained before, during, and after treatment, and the frequency of Ig and anti‐DNA antibody–secreting B cells was analyzed by enzyme‐linked immunospot assay and by analysis of Epstein‐Barr virus (EBV)–transformed B cell lines. To determine the effect of treatment on somatic mutation of Ig genes, reverse transcriptase–polymerase chain reaction was performed on messenger RNA from 4 patients, using primers specific for the DP‐47 heavy chain gene and for IgG. Finally, B cell phenotype was investigated using flow cytometry. Results: Even a brief period of treatment with anti‐CD40L markedly reduced the frequency of IgG and IgG anti‐DNA antibody–producing B cells, and these changes persisted for several months after cessation of treatment. To confirm these findings, EBV‐transformed B cell lines were screened from each of 3 patients, and a 10‐fold decrease in anti‐DNA antibody–secreting cell lines was found after treatment in all 3 patients. Few differences in mutation patterns were observed before and after treatment; however, the frequency of germline‐encoded DP‐47 sequences was significantly increased before treatment and normalized following treatment. Flow cytometric analysis of B cells revealed expansion of a CD27−/IgD− B cell subset in some of the patients, which did not change with treatment. Conclusion: These are the first mechanistic studies of the effect of anti‐CD40L therapy in human autoimmune disease. The results suggest that further studies of CD40L blockade are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Boumpas, D. T., Furie, R., Manzi, S., Illei, G. G., Wallace, D. J., Balow, J. E., Vaishnaw, A., & on behalf of the BG9588 Lupus Nephritis Trial Group (2003) · Arthritis & Rheumatism · doi:10.1002/art.10856 · Cited by 618
Self-citationWei, C., Anolik, J., Cappione, A., Zheng, B., Pugh-Bernard, A., Brooks, J., Lee, E.-H., Milner, E. C. B., & Sanz, I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6624 · Cited by 604
Dysregulation of germinal centres in autoimmune disease
Vinuesa, C. G., Sanz, I., & Cook, M. C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2637 · Cited by 464
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic
Martin, F., & Chan, A. C. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090517 · Cited by 369
Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond
Karnell, J. L., Rieder, S. A., Ettinger, R., & Kolbeck, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.005 · Cited by 334
Extrafollicular responses in humans and SLE
Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E., & Sanz, I. (2019) · Immunological Reviews · doi:10.1111/imr.12741 · Cited by 317
Jacobi, A. M., Reiter, K., Mackay, M., Aranow, C., Hiepe, F., Radbruch, A., Hansen, A., Burmester, G., Diamond, B., Lipsky, P. E., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23498 · Cited by 289
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 279
Advances in Human B Cell Phenotypic Profiling
Kaminski, D. A., Wei, C., Qian, Y., Rosenberg, A. F., & Sanz, I. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00302 · Cited by 272
CD40 and autoimmunity: The dark side of a great activator
Peters, A. L., Stunz, L. L., & Bishop, G. A. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.05.012 · Cited by 270
B cells as therapeutic targets in SLE
Sanz, I., & Lee, F. E.-H. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.68 · Cited by 261
Long-term survival of pig-to-rhesus macaque renal xenografts is dependent on CD4 T cell depletion
Kim, S. C., Mathews, D. V., Breeden, C. P., Higginbotham, L. B., Ladowski, J., Martens, G., Stephenson, A., Farris, A. B., Strobert, E. A., Jenkins, J., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15329 · Cited by 232
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Sidiropoulos, P. I., & Boumpas, D. T. (2004) · Lupus · doi:10.1191/0961203304lu1032oa · Cited by 178
Barrile, R., van der Meer, A. D., Park, H., Fraser, J. P., Simic, D., Teng, F., Conegliano, D., Nguyen, J., Jain, A., Zhou, M., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1054 · Cited by 138
“antibodies (mAbs) against CD40L can be used to suppress organ transplant rejection or autoimmunity.(7) However, the develop-”
Background
Metadata
- Authors
- Huang, W., Sinha, J., Newman, J., Reddy, B., Budhai, L., Furie, R., Vaishnaw, A., & Davidson, A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-06
- Volume
- 46
- Issue
- 6
- Pages
- 1554-1562
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2057338076
- Cited by
- 165
- References
- 0
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.